AnaptysBio spins off 100 First Tracks shares

First Tracks Biotherapeutics, Inc. reported an insider transaction by AnaptysBio, Inc., a ten percent owner, related to a corporate restructuring.

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. reported an insider transaction by AnaptysBio, Inc., a ten percent owner, related to a corporate restructuring. AnaptysBio previously held 100 shares of First Tracks common stock, which represented all issued and outstanding shares.

On the April 20, 2026 record date, AnaptysBio distributed these 100 shares to its own stockholders in a Spin-Off that occurred before the market opened that day. Following this distribution, AnaptysBio reported holding 0 shares of First Tracks common stock, indicating its ownership position in First Tracks was fully distributed.

Insider Trade Summary

Other: 100 shares

Other 1 txn

Insider ANAPTYSBIO, INC

Role 10% Owner

Type	Security	Shares	Price	Value
Other	Common Stock, par value $0.001 per share	100	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.001 per share — 0 shares (Direct)

Footnotes (3)

1. F1. On April 1, 2026, AnaptysBio, Inc., a Delaware corporation ("AnaptysBio"), reported that it owned 100 shares of common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. ("First Tracks"), which at the time constituted all of the issued and outstanding shares of common stock of First Tracks.
2. F2. The record date for the distribution by AnaptysBio of all shares of common stock of First Tracks to the holders of AnaptysBio common stock was April 20, 2026 (the "Spin-Off"). The Spin-Off occurred before the market opened on April 20, 2026.
3. F3. Represents the outstanding shares of common stock of First Tracks as of April 20, 2026, which were distributed in the Spin-Off as defined in footnote 2 on April 20, 2026.

Key Figures

Shares distributed: 100 shares Post-transaction holdings: 0 shares Par value: $0.001 per share +2 more

5 metrics

Shares distributed 100 shares Outstanding First Tracks common stock distributed in Spin-Off on April 20, 2026

Post-transaction holdings 0 shares AnaptysBio total First Tracks common shares following Spin-Off

Par value $0.001 per share Par value of First Tracks common stock reported in the Form 4

Record date April 20, 2026 Record date for Spin-Off distribution of First Tracks shares

Spin-Off timing Before market open Timing of First Tracks share distribution on April 20, 2026

Key Terms

Spin-Off, record date, ten percent owner, Common Stock, par value $0.001 per share, +1 more

5 terms

Spin-Off financial

"The record date for the distribution ... was April 20, 2026 (the "Spin-Off")."

A spin-off happens when a company creates a new, independent business by separating part of itself, like splitting off a division into its own company. This often happens so the new company can focus better on its own goals or attract different investors. It matters because it can lead to more growth opportunities and clearer focus for both companies.

record date financial

"The record date for the distribution by AnaptysBio of all shares ... was April 20, 2026"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

ten percent owner regulatory

"reporting person is marked as a ten percent owner of First Tracks Biotherapeutics, Inc."

Common Stock, par value $0.001 per share financial

"security_title: "Common Stock, par value $0.001 per share""

Other acquisition or disposition regulatory

"transaction_code_description: "Other acquisition or disposition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AnaptysBio report for First Tracks Biotherapeutics (TRAXV)?

AnaptysBio reported an "other" transaction involving 100 shares of First Tracks common stock. These shares were distributed to AnaptysBio stockholders in a Spin-Off on April 20, 2026, leaving AnaptysBio with no remaining First Tracks shares afterward.

How many First Tracks Biotherapeutics (TRAXV) shares were involved in the reported Form 4?

The Form 4 reports 100 shares of First Tracks common stock. Footnotes explain these 100 shares represented all issued and outstanding First Tracks common stock and were distributed by AnaptysBio to its own stockholders in the Spin-Off on April 20, 2026.

What is the Spin-Off described between AnaptysBio and First Tracks Biotherapeutics (TRAXV)?

The Spin-Off refers to AnaptysBio’s distribution of all 100 outstanding shares of First Tracks common stock to AnaptysBio stockholders. The record date for this distribution was April 20, 2026, and the Spin-Off occurred before the market opened on that date.

What was AnaptysBio’s ownership in First Tracks Biotherapeutics (TRAXV) before the Spin-Off?

Before the Spin-Off, AnaptysBio owned 100 shares of First Tracks common stock. Footnotes state these 100 shares constituted all issued and outstanding First Tracks common stock as of April 1, 2026, giving AnaptysBio full ownership at that time.

How many First Tracks Biotherapeutics (TRAXV) shares did AnaptysBio hold after the Spin-Off?

After the Spin-Off distribution on April 20, 2026, AnaptysBio reported holding 0 shares of First Tracks common stock. The Form 4 shows total shares following the transaction as 0.0000, reflecting the complete distribution of its previously held 100 shares.

What does transaction code J mean in the First Tracks Biotherapeutics (TRAXV) Form 4?

Transaction code J indicates "other acquisition or disposition" rather than a straightforward purchase or sale. In this case, it reflects a restructuring-related event, where 100 shares of First Tracks common stock were distributed in a Spin-Off by AnaptysBio to its stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANAPTYSBIO, INC

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 9212

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share(1)	04/20/2026		J(2)		100(3)	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 1, 2026, AnaptysBio, Inc., a Delaware corporation ("AnaptysBio"), reported that it owned 100 shares of common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. ("First Tracks"), which at the time constituted all of the issued and outstanding shares of common stock of First Tracks.

2. The record date for the distribution by AnaptysBio of all shares of common stock of First Tracks to the holders of AnaptysBio common stock was April 20, 2026 (the "Spin-Off"). The Spin-Off occurred before the market opened on April 20, 2026.

3. Represents the outstanding shares of common stock of First Tracks as of April 20, 2026, which were distributed in the Spin-Off as defined in footnote 2 on April 20, 2026.

	/s/ Dan Faga, Chief Executive Officer and President of AnaptysBio, Inc.	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)